<DOC>
	<DOC>NCT02175212</DOC>
	<brief_summary>The present study is a phase III randomized and multicentric trial evaluating the potential additional impact effect of two years adjuvant androgen deprivation when combined with neoadjuvant (4 months) and high-dose (76 Gy) conformal radiotherapy in moderate high-risk prostate cancer patients. Stratification will be performed by prognostic factors and by participating institution.</brief_summary>
	<brief_title>Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Estrogens, Conjugated (USP)</mesh_term>
	<criteria>Histological proven adenocarcinoma of the prostate Stage: cT1c3b N0M0 according to American Joint Committee on Cancer (AJCC) Tumor Node Metastasis (TNM) Prostatic Specific Antigen (PSA)&lt;100 ng/ml Intermediate (T1T2 with Gleason Score [GS] 7 and/or PSA 1020) High risk (T3 and/or GS 810 and/or PSA &gt; 20) Karnofsky Index (KI) performance status â‰¥70% Written informed consent T4 N1 M1, Previous surgical treatment (prostatectomy or cryosurgery) Neoadjuvant hormonal treatment &gt; 3 months. History of pelvic radiotherapy (RT) Contraindications for radiotherapy Concomitant use of chemotherapy Serious psychiatric or medical condition Current synchronic malignancies</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Patients with prostate adenocarcinoma</keyword>
</DOC>